Akebia Therapeutics Inc. AKBA

NAS: AKBA | ISIN: US00972D1054   19/04/2024
1,360 USD (-2,16%)
(-2,16%)   19/04/2024

2 april 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 maart 2024 · Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis · Persbericht

14 maart 2024 · Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights · Persbericht

11 maart 2024 · Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results · Persbericht

1 maart 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

2 februari 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

30 januari 2024 · Akebia Secures $55 Million Term Loan Financing · Persbericht

9 januari 2024 · Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer · Persbericht

2 januari 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 december 2023 · Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

1 december 2023 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 november 2023 · Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

2 november 2023 · Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors · Persbericht

1 november 2023 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

31 oktober 2023 · Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights · Persbericht

25 oktober 2023 · Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease · Persbericht

18 oktober 2023 · Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023 · Persbericht

3 oktober 2023 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 september 2023 · Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat · Persbericht

26 september 2023 · Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update · Persbericht

Mijn selecties